Methods and compositions for modulating prostasin

Abstract

The invention provides methods and compositions related to modulating prostasin.

1 . A method of modulating prostasin activity in a subject, said method comprising administering to the subject an antagonist, whereby prostasin activity is modulated in the subject,
 wherein the antagonist is (a) an antagonist that disrupts physiological inhibition of prostasin, wherein the antagonist is capable of inhibiting HAI-1/1B inhibition of prostasin activity, or (b) an antagonist of prostasin, said antagonist consisting or consisting essentially of at least a portion of KD1 (SEQ ID NO:2;  FIG. 6 ).   
     
     
         2 . A method of treating a pathological condition associated with downregulation of prostasin in a subject, said method comprising administering to the subject the antagonist of  claim 3  or  4 , whereby prostasin activity is increased. 
     
     
         3 . A method of treating a pathological condition associated with upregulation of prostasin in a subject, said method comprising administering to the subject an antagonist that inhibits prostasin activity, whereby prostasin activity is decreased. 
     
     
         4 . A method of reducing physiological inhibition of prostasin activity in a subject having a pathological condition associated with down-regulation of prostasin activity, said method comprising administering to the subject the antagonist of  claim 3  or  4 , whereby prostasin activity is enhanced. 
     
     
         5 . A method of treating a subject having a pathological condition associated with dysregulated sodium channel function and sub-normal prostasin activity, said method comprising administering to the subject the antagonist of  claim 3  or  4 , whereby prostasin activity is enhanced. 
     
     
         6 . A method of treating a subject having cancer at a stage associated with sub-normal prostasin activity, said method comprising administering to the subject the antagonist of  claim 3  or  4 , whereby prostasin activity is enhanced. 
     
     
         7 . The method of  claim 6 , wherein the cancer is high-grade prostate cancer. 
     
     
         8 . The method of  claim 7 , wherein the cancer is hormone-refractory prostate cancer. 
     
     
         9 . The method of  claim 6 , wherein the cancer is invasive prostate cancer. 
     
     
         10 . A method of treating a pathological condition associated with dysregulation of prostasin in a subject, said method comprising administering to the subject an effective amount of an antagonist wherein the antagonist is (a) an antagonist that disrupts physiological inhibition of prostasin, wherein the antagonist is capable of inhibiting HAI-1/1B inhibition of prostasin activity, or (b) an antagonist of prostasin, said antagonist consisting or consisting essentially of at least a portion of KD1 (SEQ ID NO:2;  FIG. 6 ), whereby said condition is treated. 
     
     
         11 . A method of therapeutically treating a mammal having a cancerous tumor comprising a cell that expresses prostasin and/or HAI-1/1B, said method comprising administering to said mammal an effective amount of an antagonist of prostasin and/or HAI-1/1B, thereby effectively treating said mammal 
     
     
         12 . A method for treating or preventing a cell proliferative disorder associated with dysregulated activity of prostasin and/or HAI-1/1B, or both, said method comprising administering to a subject an effective amount of an antagonist of prostasin and/or HAI-1/1B, thereby effectively treating or preventing said cell proliferative disorder.